Testing more frequent VCN-01 with standard chemo for new pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic pancreatic cancer that was just diagnosed and you haven't had any treatment for it yet.
- You are generally active (can do light housework or office work) and able to take care of yourself.
- Your liver, kidneys, and blood counts are working well enough based on recent blood tests.
- You don't have serious infections like active hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
This trial tests a new type of vaccine (called ONVAX-01) combined with an immunotherapy drug and chemotherapy for advanced pancreatic cancer. The goal is to see if this combination can help your immune system fight the cancer more effectively than the usual treatments alone.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
This trial tests a new treatment called VRT106 combined with chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
Hear when a new Pancreas Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.